Consequently, further experimental and clinical studies of IL-1 and IL-6 are warranted and may provide a better understanding of interleukin-associated changes to the microenvironment associated with ovarian cancer progression leading to improved prognosis by novel treatment options. Here, IL1B is linked to ovarian carcinoma.